LifeMD Launches Novo Nordisk Wegovy Subscription Program, Patients Save Up to $1,200
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy LFMD?
LifeMD (LFMD) announced the launch of Novo Nordisk's (NVO) new Wegovy subscription program is now available through LifeMD. "The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations and $600 for oral therapy," LifeMD said in a statement. LifeMD shares are up 6% to $3.81 in premarket trading.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFMD
Wall Street analysts forecast LFMD stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.600
Low
6.00
Averages
9.67
High
15.00
Current: 3.600
Low
6.00
Averages
9.67
High
15.00
About LFMD
LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
LifeMD Appoints New CFO, Shares Rise 7%
- Executive Change: LifeMD appointed Atul Kavthekar as CFO effective March 16, replacing Marc Benathen, who will remain until March 31, 2026, to ensure a smooth leadership transition, highlighting the company's commitment to stability in its executive team.
- Stock Surge: Following the announcement, LifeMD shares rose nearly 7% in premarket trading, reflecting market confidence in the new CFO and optimistic expectations for the company's future growth trajectory.
- Financial Targets: LifeMD outlined a target of over $250 million in annualized revenue run rate by Q4 2026, driven by record demand for GLP-1 drugs and expanded partnerships, indicating the company's strategy to capitalize on a rapidly growing market.
- Analyst Rating: Cantor Fitzgerald reiterated its Overweight rating on LifeMD after the company reported strong Q4 results, demonstrating analysts' positive outlook on the company's future performance, which may further bolster investor confidence.
See More
LifeMD Appoints New CFO to Support Growth Phase
- Executive Change: LifeMD has appointed Atul Kavthekar as the new CFO effective immediately, a move aimed at supporting the company's next phase of growth, indicating a strong commitment to future development.
- Transition Plan: Current CFO Marc Benathen will remain until March 31, 2026, to ensure a smooth transition, which helps maintain operational stability and continuity within the company.
- Positive Market Reaction: Following the CFO appointment, LifeMD's shares rose, reflecting investor confidence in the company's future, particularly after Cantor Fitzgerald reiterated its Overweight rating.
- Optimistic Financial Outlook: LifeMD's strong performance in Q4 2025 further bolstered market confidence in the company's financial health, laying a solid foundation for future growth.
See More
LifeMD Appoints New CFO and Executives
- Executive Changes: LifeMD has appointed Atul Kavthekar as CFO effective immediately, while current CFO Marc Benathen will depart on March 31 to support the transition, indicating a strategic shift in leadership.
- Market Reaction: In pre-market trading, LFMDP shares rose 7.28% to $4.2697 on Nasdaq, reflecting investor optimism regarding the new leadership team.
- New CFO Background: Kavthekar brings nearly three decades of financial leadership experience across healthcare, pharmacy, and e-commerce, and is expected to leverage his expertise in capital markets and M&A to drive company growth.
- New Marketing Strategy: Chris Pisano has been appointed as CMO, overseeing brand strategy and digital marketing, and with over 25 years of industry experience, aims to enhance LifeMD's market positioning and brand impact.
See More
LifeMD Stock Soars After Strong Q4 Performance and Upgraded Rating
- Stock Surge: LifeMD's stock soared by as much as 23.56% to $3.86 on Tuesday after Cantor Fitzgerald reiterated its Overweight rating, reflecting strong market confidence in the company's growth prospects.
- Performance Beat: The company reported a Q4 loss of $0.04 per share with revenue increasing by 3.9% to $46.87 million, both metrics exceeding analyst expectations, indicating the effectiveness of its business model.
- Cautious Guidance: Although Q1 revenue guidance of $48 million to $49 million fell short of the $49.33 million consensus, the full-year revenue forecast of $220 million to $230 million remains above market expectations.
- Profitability Outlook: LifeMD anticipates returning to profitability in Q2 as customer acquisition costs decline and patient volumes surge, projecting an annualized revenue run rate exceeding $250 million and adjusted EBITDA surpassing $25 million by Q4 2026.
See More
LifeMD Reports Strong Q4 and Full Year 2025 Earnings Growth
- Significant Revenue Growth: LifeMD reported Q4 2025 revenue of $46.9 million, a 4% year-over-year increase, with full-year revenue reaching $194.1 million, reflecting a robust 25% growth that underscores the company's strong market performance and growth potential.
- Margin Fluctuations: While the gross margin for Q4 2025 improved to 87.1%, an increase of 570 basis points year-over-year, the full-year gross margin slightly decreased to 85.7%, indicating challenges in cost management and profitability.
- Cash Flow and Subscriber Growth: By the end of 2025, LifeMD held $36.8 million in cash with no debt, and active subscribers approached 323,000, marking a 16% year-over-year increase, providing a solid financial foundation for future expansion and investments.
- Future Outlook and Challenges: The company anticipates Q1 2026 revenue between $48 million and $49 million, facing high customer acquisition costs and competitive pressures, yet continues to invest in marketing and AI technologies to enhance operational efficiency.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
LifeMD Appoints New CFO, Shares Rise 7%
- Executive Change: LifeMD appointed Atul Kavthekar as CFO effective March 16, replacing Marc Benathen, who will remain until March 31, 2026, to ensure a smooth leadership transition, highlighting the company's commitment to stability in its executive team.
- Stock Surge: Following the announcement, LifeMD shares rose nearly 7% in premarket trading, reflecting market confidence in the new CFO and optimistic expectations for the company's future growth trajectory.
- Financial Targets: LifeMD outlined a target of over $250 million in annualized revenue run rate by Q4 2026, driven by record demand for GLP-1 drugs and expanded partnerships, indicating the company's strategy to capitalize on a rapidly growing market.
- Analyst Rating: Cantor Fitzgerald reiterated its Overweight rating on LifeMD after the company reported strong Q4 results, demonstrating analysts' positive outlook on the company's future performance, which may further bolster investor confidence.
See More
LifeMD Appoints New CFO to Support Growth Phase
- Executive Change: LifeMD has appointed Atul Kavthekar as the new CFO effective immediately, a move aimed at supporting the company's next phase of growth, indicating a strong commitment to future development.
- Transition Plan: Current CFO Marc Benathen will remain until March 31, 2026, to ensure a smooth transition, which helps maintain operational stability and continuity within the company.
- Positive Market Reaction: Following the CFO appointment, LifeMD's shares rose, reflecting investor confidence in the company's future, particularly after Cantor Fitzgerald reiterated its Overweight rating.
- Optimistic Financial Outlook: LifeMD's strong performance in Q4 2025 further bolstered market confidence in the company's financial health, laying a solid foundation for future growth.
See More
LifeMD Appoints New CFO and Executives
- Executive Changes: LifeMD has appointed Atul Kavthekar as CFO effective immediately, while current CFO Marc Benathen will depart on March 31 to support the transition, indicating a strategic shift in leadership.
- Market Reaction: In pre-market trading, LFMDP shares rose 7.28% to $4.2697 on Nasdaq, reflecting investor optimism regarding the new leadership team.
- New CFO Background: Kavthekar brings nearly three decades of financial leadership experience across healthcare, pharmacy, and e-commerce, and is expected to leverage his expertise in capital markets and M&A to drive company growth.
- New Marketing Strategy: Chris Pisano has been appointed as CMO, overseeing brand strategy and digital marketing, and with over 25 years of industry experience, aims to enhance LifeMD's market positioning and brand impact.
See More
LifeMD Stock Soars After Strong Q4 Performance and Upgraded Rating
- Stock Surge: LifeMD's stock soared by as much as 23.56% to $3.86 on Tuesday after Cantor Fitzgerald reiterated its Overweight rating, reflecting strong market confidence in the company's growth prospects.
- Performance Beat: The company reported a Q4 loss of $0.04 per share with revenue increasing by 3.9% to $46.87 million, both metrics exceeding analyst expectations, indicating the effectiveness of its business model.
- Cautious Guidance: Although Q1 revenue guidance of $48 million to $49 million fell short of the $49.33 million consensus, the full-year revenue forecast of $220 million to $230 million remains above market expectations.
- Profitability Outlook: LifeMD anticipates returning to profitability in Q2 as customer acquisition costs decline and patient volumes surge, projecting an annualized revenue run rate exceeding $250 million and adjusted EBITDA surpassing $25 million by Q4 2026.
See More
LifeMD Reports Strong Q4 and Full Year 2025 Earnings Growth
- Significant Revenue Growth: LifeMD reported Q4 2025 revenue of $46.9 million, a 4% year-over-year increase, with full-year revenue reaching $194.1 million, reflecting a robust 25% growth that underscores the company's strong market performance and growth potential.
- Margin Fluctuations: While the gross margin for Q4 2025 improved to 87.1%, an increase of 570 basis points year-over-year, the full-year gross margin slightly decreased to 85.7%, indicating challenges in cost management and profitability.
- Cash Flow and Subscriber Growth: By the end of 2025, LifeMD held $36.8 million in cash with no debt, and active subscribers approached 323,000, marking a 16% year-over-year increase, providing a solid financial foundation for future expansion and investments.
- Future Outlook and Challenges: The company anticipates Q1 2026 revenue between $48 million and $49 million, facing high customer acquisition costs and competitive pressures, yet continues to invest in marketing and AI technologies to enhance operational efficiency.
See More
